A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With LAF237 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Phase of Trial: Phase III
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Oct 2012 Planned End Date changed from 1 Mar 2014 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 29 Dec 2011 New trial record